肺炎ワクチンの市場規模：ワクチンタイプ、製品タイプ、分野、流通チャネル、地域別、2024年～2031年

肺炎ワクチン市場評価、2024年～2031年

世界的に肺炎球菌感染症への関心が高まっており、ワクチン接種の需要が高まっています。これには、抗生物質耐性菌の出現や肺炎にかかりやすい高齢化社会が含まれます。第二に、特に小児や高リスク者に対する肺炎球菌予防接種の意義について、政府の施策や国民の意識向上キャンペーンの増加により、予防接種率が顕著に増加しています。このような理由から肺炎予防接種市場は活況を呈しており、老舗企業も最近参入した企業も、効率的な予防薬に対するニーズの高まりに応えるべくしのぎを削っています。市場の拡大を牽引することで、2023年の市場売上高は99億3,000万米ドルを超え、2031年には143億米ドルに達すると予測されています。

さらに、メルク社が最近承認した21価のキャップヴァクシブなどのワクチンがカバーできる血清型の数を増やすことも、調査の目標です。経鼻スプレーは、ワクチンの受容性を高め、免疫反応を高めるために研究されている新しい送達技術の一例です。さらに、予防接種に対する免疫系の反応を強化する新しいアジュバントが、複数の呼吸器感染症を対象とする混合ワクチンの開発や、より長期の防御に使用できるかどうかの研究も行われています。これらの開発により、将来、より実用的で効果的な肺炎予防接種が開発される可能性があります。同市場は、今後数年間で着実に上昇し、2024年から2031年までのCAGRは約5.15%で成長すると予想されます。

肺炎ワクチン市場の定義/概要

肺炎ワクチン市場は、肺炎の主な原因である肺炎球菌による感染を予防する予防接種の発見、製造、流通を担っています。これらの予防接種は、高齢者や小さな子供などの感染しやすいグループを守るために、小児や成人の予防接種レジメンの一部として実施されます。肺炎球菌感染症に対する世界の認識の拡大、抗生物質耐性の開発、人口の高齢化により、市場の将来性は明るいと思われます。新しいデリバリー技術や幅広い予防スペクトルを持つ予防接種は、市場拡大を促進する技術開発の一例です。特に、ワクチン接種を奨励する政府のキャンペーンと相まって、今後数年間は肺炎ワクチン市場が健全に推移すると思われます。

肺炎球菌疾患の負担増は肺炎ワクチン市場の成長を促進するか？

肺炎球菌感染症、髄膜炎、敗血症のような肺炎球菌感染症に関連する有病率と死亡率の増加は、肺炎ワクチン市場の成長を促進する主な要因です。世界保健機関（WHO）は、特に幼児や高齢者のような社会的弱者の間で年間150万人以上が死亡していると推定しており、予防対策の必要性が極めて重要になっています。肺炎ワクチンは、この重大な疾病負担と闘うための強力な手段を提供し、ワクチン接種努力の増加とワクチン市場の成長をもたらしています。

肺炎ワクチン市場は、肺炎球菌感染症の原因菌である肺炎球菌の抗生物質耐性株の増加から大きな影響を受けています。このような抗生物質耐性菌によって現在の治療法が有効でなくなった場合、予防接種が最も現実的な防御策となります。抗生物質が効かなくなりつつあるため、肺炎ワクチンの市場はいずれ発展し、特に高齢者や小さな子供といった弱い立場の人々を守るために、ワクチン接種が受け入れられるようになると思われます。

公衆衛生への取り組みと意識の高まりが、肺炎ワクチン市場を牽引しています。肺炎球菌ワクチン接種の価値は、公衆衛生キャンペーンや政府主催の予防接種プログラムによって、特に高齢者や小児のようなハイリスク集団に対して効果的に強調されています。これにより、より多くの人々がワクチン接種を受けるようになり、それが直ちに肺炎ワクチンの需要増につながり、ヘルスケア団体によるアドボカシー活動とともに市場成長を促進しています。

さらに、肺炎ワクチン市場を促進している主な要因の1つは、小児期の予防接種プログラムに肺炎球菌ワクチンの接種を含めることを重視していることです。この戦略には2つの利点があります。まず第一に、肺炎球菌感染症にかかりやすい脆弱な集団である幼児を特に保護することができます。第二に、小児を対象とした地域全体の予防接種キャンペーンは、集団免疫の開発に役立ちます。一般市民は、この間接的な保護によって守られており、これには、高齢であったり、基礎疾患があったりして予防接種を受けることができない人々も含まれます。このため、世界中で小児の予防接種率が上昇しており、肺炎ワクチンの需要を押し上げ、市場を拡大しています。

新世代の肺炎球菌ワクチンの発見により、肺炎ワクチン市場は大幅に拡大すると予想されます。肺炎球菌による疾病の負担に対処する緊急性が高まっているため、製薬会社は研究開発への投資を増やしています。このような取り組みにより、様々な利点を持つ次世代予防接種の開発が促進されています。次世代予防接種は、より幅広い血清型をカバーすることで、より多様な肺炎球菌株に対する防御を提供する可能性があります。また、免疫の持続時間が長くなり、繰り返し予防接種を受ける必要性が減るかもしれないです。改良された能力を持つ次世代予防接種の登場は、政府やヘルスケアプロバイダーに新たな機会を提供するものです。研究者たちがこの病気と闘うためのより強力な方法を探しているため、こうした次世代肺炎ワクチンの需要は増加し、業界全体を前進させると予想されます。

ワクチン費用の高騰は肺炎ワクチン市場の成長を妨げるか？

ワクチン費用の高騰は肺炎ワクチン市場の成長に大きな脅威となります。肺炎ワクチンの市場開拓は、新興国市場におけるワクチン接種費用の低さによって大きく阻害されています。多くの新興諸国にとって、これらの予防接種の開発、製造、流通には多大な費用がかかるため、手が出ないです。予防接種の普及は、肺炎球菌ワクチンを国の予防接種プログラムに組み入れる能力に対するこの制限によって妨げられています。その結果、これらの国の人口のかなりの部分、特に高齢者や小児は、依然として肺炎球菌感染症に罹患しやすいです。世界人口のかなりの部分は、こうした救命のための予防接種を受ける余裕がないため、手ごろな価格の欠如が市場拡大の深刻な障害となっています。

市場全体の成長は、肺炎予防接種の高コストがもたらす不均等なアクセスと市場の飽和によって阻害される可能性があります。これらのワクチンを容易に購入し、提供する能力は、裕福な国や民間のヘルスケア従事者の間でより高いかもしれないです。しかし、この経済的不平等が大きな課題となっています。資金が限られている新興国では、公的イニシアチブを維持することが難しいです。このため、新興国の人口の大部分、特に高齢者や小さな子どもといった最も弱い立場にある人々は、不平等な市場環境の中で無防備なままです。世界市場の大部分は、ワクチン接種を受ける能力が著しく制限されているため、潜在的な接種対象者が未開拓のまま放置され、全体的な成長を妨げています。

ワクチン接種費用の高騰は、肺炎球菌ワクチンの市場拡大を阻害する可能性があります。自己負担費用のため、公的ヘルスケアへのアクセスが乏しい地域に住む人々は、予防接種に高額な費用がかかると接種を躊躇する可能性があります。その結果、住民の予防接種率が低下する可能性があります。集団免疫（間接的防御がワクチン未接種者をも保護する重要なポイント）は、ワクチン接種率が低いと達成するのが難しくなります。集団免疫の欠如により、ワクチン接種者を含むすべての国民が伝染病にかかりやすくなります。ワクチン接種率が低いため、公衆衛生当局は、総合的な利益が小さいワクチン接種に費用をかけることに消極的になる可能性があります。

さらに、ワクチン開発に伴う多額の初期費用が、肺炎ワクチン産業への新規参入の抑止力となる可能性もあります。このような競合の欠如は、様々な意味でイノベーションを阻害する可能性があります。まず、研究開発に従事する企業が少ないため、調査される視点や方法が少なくなります。これは新しい予防接種の創出を完全に止めてしまう可能性があります。第二に、ライバルが少なければ、既存の企業は特に発展途上国向けに作られた予防接種や、費用対効果を重視した予防接種に集中する傾向が弱まるかもしれないです。その結果、発展途上国特有の要件を満たし、世界の予防接種率を向上させるような、より利用しやすい、あるいは最先端の予防接種の創造が妨げられる可能性があります。

さらに、予防接種プログラムの取得と実施にかかる初期費用が高額であることが、政策立案者に影響を与える可能性もあります。このような取り組みがもたらす長期的なメリットに気付かない可能性もあります。肺炎球菌感染症は、予防接種を受けた集団で大幅に減少するため、入院や治療など、ヘルスケアシステムへの財政的負担が軽減されます。さらに、より健康な労働力は経済の拡大を支えることができます。しかし、こうした長期的なメリットが考慮されないと、意思決定者は予防接種キャンペーンへの資金提供に消極的になります。このようなビジョンの欠如は、悪循環を引き起こす可能性があります。予防接種率の低下による疾病負担の増加は、ヘルスケアシステムへの負担を増大させ、最終的に総費用を増加させる。このことは、予防接種は高額であるという当初の思い込みを裏付け、投資を抑制し、肺炎ワクチン市場の拡大を制限します。

目次

第1章 世界の肺炎ワクチン市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 肺炎ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル

第5章 肺炎ワクチンの世界市場：ワクチンタイプ別

• 概要
• 肺炎球菌結合型ワクチン
• 肺炎球菌多糖体ワクチン

第6章 肺炎ワクチンの世界市場：製品タイプ別

• 概要
• プレブナール13
• シンフロリックス
• ニューモバックス 23

第7章 肺炎ワクチンの世界市場、セクター別

• 概要
• 公共
• 民間

第8章 肺炎ワクチンの世界市場：流通チャネル別

• 概要
• 流通パートナー企業
• 非政府組織（NGO）
• 政府機関

第9章 肺炎ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の肺炎ワクチン市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi Pasteur
• Serum Institute of India Pvt Ltd.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• CSL Limited
• Bharat Biotech International Limited

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Pneumonia Vaccine Market Valuation - 2024-2031

The rising concern in pneumococcal infections globally is fueling demand for vaccination. This includes the advent of antibiotic-resistant bacterial strains and an aging population that is more prone to pneumonia. Second, there is a notable increase in vaccination rates due to increased government measures and public awareness campaigns about the significance of pneumococcal immunization, especially for children and high-risk persons. The market for pneumonia vaccinations is booming as a result of these reasons, and both long-standing companies and recent arrivals are fighting to supply the rising need for efficient prophylactics. driving market expansion is predicted to push market sales above USD 9.93 Billion in 2023 and reach USD 14.3 Billion by 2031.

Furthermore, the goal of the research is to increase the number of serotypes that vaccines, such as Merck's recently authorized 21-valent Capvaxive, can cover. Intranasal sprays are one example of a novel delivery technique being investigated to enhance vaccine acceptability and maybe enhance immune response. Additionally, research is being done to see whether new adjuvants, which strengthen the immune system's reaction to the vaccination, can be used to develop combination vaccines that target several respiratory infections or even longer-lasting protection. These developments could lead to the development of more practical and effective pneumonia vaccinations in the future. The market is expected to rise steadily in the coming years to grow at a CAGR of about 5.15% from 2024 to 2031.

Pneumonia Vaccine Market Definition/ Overview

The discovery, manufacturing, and distribution of vaccinations that guard against infection by Streptococcus pneumoniae, a primary cause of pneumonia, are served by the pneumonia vaccine market. These vaccinations are administered as part of childhood and adult immunization regimens in order to safeguard susceptible groups, such as the elderly and small children. Due to expanding global awareness of pneumococcal infections, developing antibiotic resistance, and an aging population, the market's future potential appears bright. New delivery techniques and vaccinations with a wider spectrum of protection are examples of technological developments that should propel market expansion. This will probably result in a healthy market for pneumonia vaccines in the upcoming years, especially when combined with government campaigns encouraging vaccination.

Will the Growing Burden of Pneumococcal Disease Fuel the Growth of the Pneumonia Vaccine Market?

The growing burden of pneumococcal disease is a major driver propelling the pneumonia vaccine market forward, the rising prevalence and mortality associated with pneumococcal infections like pneumonia, meningitis, and sepsis is a major driver for the growth of the pneumonia vaccine market. With the World Health Organization estimating over 1.5 million deaths annually, particularly among vulnerable populations like young children and older adults, the need for preventative measures becomes crucial. Pneumonia vaccines offer a powerful tool to combat this significant disease burden, leading to increased vaccination efforts and market growth for these vaccines.

The market for pneumonia vaccines is significantly influenced by the rise of antibiotic-resistant strains of Streptococcus pneumoniae, the bacteria that causes pneumococcal infections. When current therapies become less effective due to these antibiotic-resistant bacteria, immunization becomes the most practical defense. The market for pneumonia vaccines will eventually develop because of the increasing ineffectiveness of antibiotics, which will also probably increase vaccination acceptance, especially to protect vulnerable groups like elderly people and small children.

Growing public health initiatives and awareness are driving the market for pneumonia vaccines. The value of pneumococcal vaccination is being effectively highlighted by public health campaigns and government-sponsored immunization programs, especially for high-risk populations like the elderly and children. This is incentivizing more people to get vaccinated, which is immediately translating to an increase in demand for pneumonia vaccines and driving market growth, along with advocacy efforts by healthcare organizations.

Furthermore, one of the main factors propelling the pneumonia vaccine market is the emphasis on including pneumococcal vaccinations in childhood immunization programs. This strategy provides two advantages. First and foremost, it specifically shields young children, a vulnerable group that is more susceptible to pneumococcal infections. Second, community-wide immunization campaigns for children aid in the development of herd immunity. The general public is protected by this indirect protection, which also includes people who are too old or have underlying medical issues to receive a vaccination. Because of this, rising children immunization rates around the world are driving up demand for pneumonia vaccines and expanding the market.

The market for pneumonia vaccines is expected to increase significantly due to the discovery of new-generation pneumococcal vaccines. Pharmaceutical companies are investing more in research and development because of the growing urgency to address the burden of pneumococcal illnesses. The development of next-generation vaccinations with various benefits is being facilitated by these initiatives. They might provide protection against a greater variety of pneumococcal strains by providing broader serotype coverage. They might also offer immunity that lasts longer, which would lessen the need for repeated vaccinations. The next generation of vaccinations with improved capabilities coming down the pipeline offers governments and healthcare providers intriguing new opportunities. The demand for these next-generation pneumonia vaccines is anticipated to increase as researchers look for more potent methods to fight this illness, driving the industry as a whole forward.

Will High Vaccine Costs Hinder the Growth of the Pneumonia Vaccine Market?

The high vaccine costs pose a significant threat to the growth of the pneumonia vaccine market, the market expansion for pneumonia vaccines is significantly hampered by the low cost of vaccination in developing nations. For many developing countries, the significant expenses involved in the development, manufacturing, and distribution of these vaccinations make them unaffordable. Widespread vaccination coverage is hampered by this restriction on their capacity to incorporate pneumococcal vaccines into national immunization programs. As a result, a sizable portion of the populace in these nations, especially the elderly and children, are still susceptible to pneumococcal infections. Because a substantial section of the world's population cannot afford these life-saving vaccinations, the lack of affordability poses a serious obstacle to market expansion.

Growth in the market as a whole may be hampered by uneven access and market saturation brought on by the high cost of pneumonia vaccinations. The ability to easily afford and deliver these vaccines may be greater in wealthier nations and among private healthcare practitioners, which could result in market saturation in these areas. But this economic inequality poses a significant challenge. With constrained funding, public initiatives in emerging nations find it difficult to stay up. Due to this, a large portion of the population in developing nations-especially the most vulnerable, such as the elderly and small children-remains unprotected in an unequal market landscape. Large segments of the worldwide market are severely limited in their ability to get vaccines, which impedes overall growth by leaving a bigger pool of prospective recipients untapped.

Elevated vaccination expenses may impede the market expansion for pneumococcal vaccines. Due to out-of-pocket costs, people living in areas with little access to public healthcare may be deterred from getting vaccinated when these vaccinations are pricey. Lower immunization rates among the populace may result from this. Herd immunity, the crucial point at which indirect protection protects even the unvaccinated, is more difficult to attain at lower vaccination rates. All members of the population, including the vaccinated, are more vulnerable to epidemics due to this lack of herd immunity. Because of the low vaccination rates, public health officials could be reluctant to spend money on vaccinations that have a small overall benefit.

Additionally, the substantial initial expenses associated with vaccine development may serve as a deterrent for new entrants into the pneumonia vaccine industry. In numerous ways, this lack of competition can impede innovation. First off, fewer viewpoints and methods are being investigated as there are fewer businesses engaged in research and development. This may completely halt the creation of new vaccinations. Second, if there is little rivalry, established businesses might be less inclined to concentrate on vaccinations that are especially made for developing nations or on cost-effectiveness. This may impede the creation of more accessible or cutting-edge vaccinations that could meet the unique requirements of these areas and raise immunization rates worldwide.

Furthermore, the initial high cost of acquiring and administering immunization programs may influence policymakers. They might not realize the significant long-term advantages that these initiatives provide. Pneumococcal diseases are substantially less common in the population that receive vaccinations, which lowers the financial load on healthcare systems for things like hospital stays and treatments. Furthermore, a healthier workforce can support economic expansion. But if these long-term advantages are not considered, decision-makers can be reluctant to fund immunization campaigns. This lack of vision can result in a vicious cycle. A higher disease load from lower vaccination rates puts more strain on healthcare systems and ultimately raises total expenses. This supports the initial belief that vaccinations are expensive, which discourages investment and limits the expansion of the pneumonia vaccine market.

Category-Wise Acumens

Will Increasing Demand for Pneumococcal Conjugate Vaccine (PCV) Propel the growth of the Pneumonia Vaccine Market?

The increasing demand for Pneumococcal Conjugate Vaccines (PCVs) is a major force propelling the growth of the pneumonia vaccine market, One of the main factors propelling the market expansion for pneumonia vaccines is the increased protection that PCV vaccinations provide for kids. Pneumococcal polysaccharide vaccines (PPSVs) have a significant gap that PCV vaccines are specifically designed to fill. As their immune systems are still maturing, young children's immunological responses against PPSVs could not be as robust and durable. PCVs are conjugated to carrier proteins, which helps them overcome this obstacle. These proteins function as immune system training wheels, improving the immune system's ability to identify and react to pneumococcal bacteria. Better protection for kids during their most susceptible years-when they are most likely to have severe repercussions from pneumococcal infections-will result from this.

The market for pneumonia vaccinations is expanding due in large part to the discovery of more recent PCV vaccines with wider serotype coverage. The bacteria Pneumococcus come in a wide variety of strains, or serotypes. People may be susceptible to infection by other strains if they are only protected against a restricted number of these serotypes by traditional vaccinations. Newer PCV vaccinations, on the other hand, are being developed to provide wider serotype coverage. As a result, they can offer defense against a larger variety of pneumococcal strains, thus enhancing overall protection against pneumococcal illnesses. These new, more thorough PCV vaccines will close a significant gap in the current pneumococcal immunization techniques when they become more widely available and integrated into vaccination programs. This will spur the market for pneumonia vaccinations by increasing demand for these cutting-edge shots.

Children's hospitalizations, pneumonia cases, and pneumococcal infections all significantly decline as a result of PCV immunization campaigns. This means that when PCV vaccinations are added to regular childhood immunization programs, there will be a direct rise in demand for them. Second, the benefits of PCV immunization extend beyond personal health. These vaccines lower the burden on healthcare systems greatly by lowering childhood pneumococcal illnesses. Over time, there are significant cost savings due to a reduction in hospital stays and treatment requirements for certain disorders. This financial gain has the potential to encourage governments and medical facilities to increase their funding for PCV immunization campaigns, which would sustain the market for pneumonia vaccines.

Furthermore, as a result of its direct protection against pneumococcal infections, PCV vaccines are in higher demand as they become an essential component of childhood immunization programs. However, the effects extend beyond personal immunity. Programs for PCV immunization also help the community's herd immunity. Pneumococcal germs circulate less when more youngsters receive vaccinations. Everyone benefits from this indirect protection, even those who are unable to receive vaccinations because of age, health issues, or weakened immune systems, such as the elderly. The community as a whole is shielded from pneumococcal illness by herd immunity, which greatly slows its spread. A positive feedback loop is produced by this. As vaccination rates and herd immunity rise, the overall disease burden falls, further strengthening the case for PCV vaccination and propelling the growth of the pneumonia vaccine market.

Additionally, within the pneumonia vaccine industry, a positive cycle of growth and innovation is being driven by the increasing demand for PCV vaccines. Pharmaceutical companies have a significant incentive to engage in research and development as PCV use rises. This results in a pipeline of even more powerful next-generation PCVs. More serotype coverage may be one of these developments, offering protection against an even greater variety of pneumococcal pathogens. Furthermore, studies are being conducted to create PCVs that would provide immunity for a longer period of time, which would lessen the need for repeated vaccinations. Combination vaccinations that target respiratory disorders in addition to pneumococcus are the most promising developments. This would provide even more all-encompassing protection in a single round of vaccinations. The promise of these innovative vaccines not only fuels market growth by creating demand for new products but also holds the potential to significantly improve preventative measures against pneumococcal and other respiratory diseases in the future.

Will Increasing Usage of Prevnar 13 Drive the Growth of the Pneumonia Vaccine Market?

the increasing usage of Prevnar 13, a prominent pneumococcal conjugate vaccine (PCV) developed by Pfizer, is a significant driver of growth in the pneumonia vaccine market, With its established effectiveness, it maintains its top spot. This indicates that it has a proven track record of successfully guarding against 13 distinct serotypes of Streptococcus pneumoniae, the bacteria that causes pneumonia and other severe pneumococcal infections. Its demonstrated efficacy is vital because it gives public health initiatives and healthcare professionals credibility. Prevnar 13 has therefore been widely incorporated into childhood vaccination programs all around the world. Due to the vaccine's broad adoption, there is a correspondingly high demand, which is driving market expansion. Prevnar 13's success also clears the path for the larger PCV market by proving that this kind of vaccination works to prevent pneumococcal infections.

A significant driving force behind the commercial expansion for pneumonia vaccines is the World Health Organization's (WHO) recommendation that Prevnar 13 be included in childhood immunization programs. The safety and efficacy of this proposal are the two main determinants. With the WHO's endorsement, Prevnar 13's excellent safety profile and demonstrated effectiveness against a variety of pneumococcal strains are reassured to medical professionals and public health initiatives. This boosts self-assurance and encourages broader adoption, especially in developing nations. Prevnar 13 is in high demand as these nations increase the scope of their immunization campaigns. The market for pneumonia vaccines is expanding overall, and this is mostly due to the rising demand in a previously neglected market area. The WHO recommendation creates a ripple effect, driving not only Prevnar 13 adoption but also raising awareness and acceptance of PCV vaccines in general, paving the way for a more robust market in the future.

Additionally, the market for pneumonia vaccines is driven by a positive feedback loop created by the increased usage of Prevnar 13. Prevnar 13 immunization results in a considerable reduction in hospital stays, instances of pneumonia, and pneumococcal infections, particularly in youngsters. This results in a dual advantage. First, by shielding kids from dangerous diseases, it immediately enhances people's health results. Second, Prevnar 13 lessens the overall strain on healthcare systems by preventing certain disorders. Long-term cost reductions from pneumococcal diseases are large when there are fewer hospital admissions and treatment requirements. A sustained growth cycle for the pneumonia vaccine market is created when healthcare providers and policymakers are incentivized to invest more in Prevnar 13 immunization campaigns by these economic benefits.

Furthermore, the benefits of widespread Prevnar 13 immunization extend beyond the vaccine market and have a substantial positive impact on the economy and society. Prevnar 13 directly reduces pneumococcal infections, which in turn results in fewer healthcare expenses. Reduced rates of hospital stays, medication use, and doctor visits are caused by fewer incidences of pneumonia and other pneumococcal infections. The healthcare systems' cost reductions from these Prevnar 13 immunization programs provide a powerful incentive for further investment in the program. Moreover, there is no denying the positive effects a healthier populace has on society. Lower rates of childhood illnesses result in better general health, fewer excuses from school, and maybe a more productive workforce. This establishes a positive feedback loop in which a healthier populace gains from Prevnar 13 and strengthens the economy, which in turn drives more demand for the pneumonia vaccination.

Increasingly pharmaceutical companies are showing a great deal of interest in Prevnar 13, thanks to its established efficacy and dominant market position. This means that there will be more competition and funding for R&D. In order to beat Prevnar 13, companies are working hard to produce next-generation PCVs. It is possible that these developments will result in increased protection against a greater variety of pneumococcal strains through broader serotype coverage. Further work is being done to create PCVs that would provide longer-lasting immunity, which would lessen the need for repeated vaccines. Current innovation promises even more potent future prophylactic measures against pneumococcal illnesses, in addition to expanding the PCV market through new product options. A dynamic environment is created when new and improved PCVs hit the market, encouraging more research and development and advancing the industry as a whole.

Country/Region-wise

Will the Increasing Healthcare Expenditure in North America Drive the Pneumonia Vaccine Market?

The increasing healthcare expenditure in North America is a significant factor propelling the growth of the pneumonia vaccine market in the region, As the focus on preventive care continues to grow in North America, the demand for these vaccines is expected to rise steadily, propelling the overall market forward. especially in light of Prevnar 13. The traditional focus of healthcare was on treating pre-existing conditions, frequently at great expense. But a paradigm change is happening. Healthcare systems are realizing that vaccinations and other preventive interventions are long-term, cost-effective investments. Prevnar 13 vaccines provide a potent instrument in this strategy. They help to avoid major pneumococcal illnesses, which in turn lowers the need for costly hospital stays, treatments, and long-term care. In the long run, this results in significant cost reductions for healthcare systems. The economic advantage of Prevnar 13 and other pneumococcal vaccines, along with the evident public health benefits of decreased illness and enhanced quality of life, make them enticing options in the preventive care arena.

Growing public advocacy and knowledge are driving the North American market for pneumonia vaccines. The market gains from this tendency in two ways. First off, healthcare organizations' educational initiatives and public health campaigns are doing a great job of emphasizing the value of vaccination, especially for high-risk populations like the elderly and immunocompromised people. People are taking a more proactive approach to their health as a result of their increased awareness, actively looking out preventative measures like the Prevnar 13 vaccine. Second, this influence is amplified much more by healthcare groups' advocacy efforts. These organizations directly increase the demand for pneumonia vaccinations within the North American market by encouraging people to get vaccinated and highlighting the possible dangers of pneumococcal illnesses as well as the long-term health advantages. This rise in demand creates a positive feedback loop for the market, as it incentivizes further public awareness campaigns and educational efforts, all contributing to sustained market growth.

In North America, government reimbursement programs are a major factor driving the market for pneumonia vaccines. The expense of recommended immunizations, including pneumococcal vaccines like Prevnar 13, is financially supported by these programs, which are provided by numerous government healthcare initiatives. Many people are relieved of a significant financial burden thanks to this support, especially those who might not have been able to pay for the vaccination otherwise. These initiatives successfully broaden the target audience for pneumonia vaccinations by lowering the cost and increasing accessibility to vaccination. This results in a greater number of individuals receiving vaccinations, which immediately spurs market expansion. Moreover, government compensation schemes not only tackle financial issues but also make a clear statement about the significance of public health. Their endorsement of pneumococcal vaccination encourages a more positive public perception of these vaccines, further propelling market expansion in North America.

Additionally, investment in adult immunization programs is driving a new wave of potential in the pneumonia vaccine industry, which is being driven by North America's aging population. The growing number of people in this demographic group has increased awareness of their susceptibility to pneumococcal infections. Healthcare systems are responding by giving adult immunization programs more importance. A new market segment catering only to the demands of senior citizens is created by this emphasis on protecting them. In this setting, vaccinations such as Pneumovax 23, which provide wider serotype coverage than childhood PCV vaccines, become more significant. In addition to growing the market, the introduction of adult immunization programs ensures a consistent need for vaccinations such as Pneumovax 23. This targeted approach ensures ongoing protection for the elderly population, while simultaneously propelling the overall growth of the pneumonia vaccine market in North America.

Furthermore, because of the high cost of healthcare in North America, the market for pneumonia vaccines is fertile ground for innovation, which feeds a cycle of continual expansion. Pharmaceutical corporations are able to make significant investments in the development of next-generation vaccines due to their financial strength. A fascinating field of study is wider-spectrum PCVs. Compared to the present alternatives, these vaccinations are intended to provide protection against an even greater variety of pneumococcal strains. Furthermore, there is great potential for development into combination vaccinations that target several respiratory disorders. These combination vaccinations may provide more complete protection in a single dose, increasing patient adherence and lowering overall medical expenses. This pipeline of innovative vaccines, driven by North America's investment in R&D, not only stimulates market growth by creating new product opportunities but also holds the potential to significantly improve preventative measures against pneumococcal and other respiratory diseases in the future. This continuous cycle of innovation ensures the pneumonia vaccine market in North America remains at the forefront of preventative healthcare.

Will Rising Disease Burden in Asia-Pacific Drive the Pneumonia Vaccine Market?

The rising disease burden of pneumococcal diseases in the Asia-Pacific region is a significant driver for the pneumonia vaccine market, the market for pneumonia vaccines is expected to increase rapidly due to the increasing prevalence of pneumococcal infections in Asia-Pacific. This area presents a serious public health risk due to the high rates of sepsis, meningitis, and pneumonia. There are two aspects to this increased awareness: the public and healthcare professionals both understand how urgent the problem is. Pneumococcal vaccinations are becoming an increasingly important weapon in the fight against these illnesses, which translates into a spike in demand for efficient prevention measures. Governments and medical establishments are paying attention, stressing how critical it is to implement extensive immunization campaigns to safeguard susceptible groups, such as the elderly and children. As a result, the market for pneumonia vaccines in the Asia-Pacific region is expected to develop significantly due to rising disease rates and the growing demand for efficient prophylactic measures.

The market for pneumonia vaccines is hampered in some regions of Asia-Pacific by worries about affordability, but groups like the Vaccine Alliance, or Gavi, are stepping in to close the gap. Gavi's participation is critical because it understands how important it is to strike a balance between accessibility and affordability. Their efforts center on removing the financial barrier to increase access to pneumococcal vaccinations in underdeveloped nations. This generates a long-term sustainable market in addition to improving public health by guaranteeing increased immunization rates and a healthier populace. Gavi opens the door for greater vaccination uptake by removing barriers related to pricing, which eventually drives growth in the Asia-Pacific pneumonia vaccine market.

The market for pneumonia vaccines is experiencing a perfect storm thanks to the expansion of the healthcare infrastructure in Asia-Pacific and the rising government backing for immunization initiatives. There are two main reasons why this tendency is good. First off, improved access to immunization services in rural regions is a result of greater investment in healthcare infrastructure. More people will be able to benefit from pneumococcal vaccinations because to this expanded reach. Second, a more resilient cold chain system results from significant government backing for immunization programs. The network of refrigerated storage and transportation facilities necessary to preserve the effectiveness of vaccinations is known as a "cold chain." Governments can maximize the effectiveness of vaccinations by ensuring that they are delivered and kept under ideal conditions through the reinforcement of this cold chain infrastructure. As a result of these improvements in access and storage, the market for pneumonia vaccines in Asia-Pacific is well-positioned for significant growth.

There is a huge market potential due to the large population and high prevalence of pneumococcal infections. Pharmaceutical businesses are being drawn to engage in research and development projects that are customized to meet the unique demands of the area. Exciting developments like vaccinations that target the most common pneumococcal strains in Asia-Pacific or more reasonably priced formulations appropriate for the region's poorest nations could result from this regional focus. In addition to meeting unmet medical needs, these regional developments would open up new market opportunities and spur major growth and innovation in the Asia-Pacific pneumonia vaccine market.

Furthermore, by extending childhood immunization programs, the Asia-Pacific region is fighting pneumococcal infections, which is propelling the market for pneumonia vaccines. Pneumococcal conjugate vaccines, or PCVs, are being systematically added to several countries' immunization programs. This guarantees that kids get this vital defense when they are most susceptible, which puts them at risk for major issues. Pneumococcal illness vaccination rates are consequently increasing throughout the region. This immediately contributes to a rise in the need for pneumococcal vaccinations, which drives market expansion in Asia-Pacific. Essentially, nations that prioritize youth immunization with PCVs are protecting their young populations and establishing a stable market for pneumonia vaccines in the area.

Competitive Landscape

The pneumonia vaccine market is a dynamic field with established players like Pfizer and Sanofi Pasteur facing competition from emerging economies like China and India. The race is on to develop next-generation vaccines with broader strain coverage and potentially even combination vaccines targeting multiple respiratory illnesses. This, coupled with increasing government immunization programs and rising awareness in developing countries, is driving market growth.

Some of the prominent players operating in the Pneumonia Vaccine Market include:

Pfizer Inc.

Merck & Co. Inc.

GlaxoSmithKline plc

AstraZeneca plc

Sanofi Pasteur

Serum Institute of India Pvt Ltd.

Abbott Laboratories

Hoffmann-La Roche Ltd.

CSL Limited

Bharat Biotech International Limited

Incheon Vaccine Ltd.

Beijing Minhai Biotechnology Co. Ltd.

Lanzhou Institute of Biological Products Co. Ltd.

Walvax Biotechnology Co. Ltd.

Xiamen Innovax Biotech Co. Ltd.

Dynavax Technologies Corporation

Hirom Abbiotec Co. Ltd.

VaxiBio Inc.

Imugene Limited

Latest Developments

In June 2024, Merck Won US FDA Approval for Capvaxive, a 21-valent pneumococcal vaccine targeting a broader range of strains compared to existing options. This could disrupt the market share currently dominated by Pfizer's Prevnar 20 vaccine. The CDC is expected to decide on recommending Capvaxive for adults over 50 later this month. Merck is aiming for Capvaxive to become the preferred choice due to its wider strain coverage.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL PNEUMONIA VACCINE MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL PNEUMONIA VACCINE MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model

5. GLOBAL PNEUMONIA VACCINE MARKET, BY VACCINE TYPE

• 5.1. Overview
• 5.2 Pneumococcal Conjugate Vaccine
• 5.3 Pneumococcal Polysaccharide Vaccine

6. GLOBAL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE

• 6.1. Overview
• 6.2. Prevnar 13
• 6.3. Synflorix
• 6.4. Pneumovax 23

7. GLOBAL PNEUMONIA VACCINE MARKET, BY SECTOR

• 7.1. Overview
• 7.2 Public
• 7.3 Private

8. GLOBAL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 8.1. Overview
• 8.2 Distribution Partner Companies
• 8.3 Non-government Organizations (NGOs)
• 8.4 Government Authorities

9. GLOBAL PNEUMONIA VACCINE MARKET, BY GEOGRAPHY

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Rest of Europe
• 9.4. Asia Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest of Asia Pacific
• 9.5. Rest of the World
  • 9.5.1. Latin America
  • 9.5.2. Middle East & Africa

10. GLOBAL PNEUMONIA VACCINE MARKET COMPETITIVE LANDSCAPE

• 10.1. Overview
• 10.2. Company Market Ranking
• 10.3. Key Development Strategies

11. COMPANY PROFILES

• 11.1. Pfizer Inc.
  • 11.1.1. Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Outlook
  • 11.1.4. Key Developments
• 11.2. Merck & Co. Inc.
  • 11.2.1. Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Outlook
  • 11.2.4. Key Developments
• 11.3. GlaxoSmithKline plc
  • 11.3.1. Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Outlook
  • 11.3.4. Key Developments
• 11.4. AstraZeneca plc
  • 11.4.1. Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Outlook
  • 11.4.4. Key Developments
• 11.5. Sanofi Pasteur
  • 11.5.1. Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Outlook
  • 11.5.4. Key Developments
• 11.6. Serum Institute of India Pvt Ltd.
  • 11.6.1. Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Outlook
  • 11.6.4. Key Developments
• 11.7. Abbott Laboratories
  • 11.7.1. Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Outlook
  • 11.7.4. Key Developments
• 11.8. F. Hoffmann-La Roche Ltd.
  • 11.8.1. Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Outlook
  • 11.8.4. Key Developments
• 11.9. CSL Limited
  • 11.9.1. Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Outlook
  • 11.9.4. Key Developments
• 11.10. Bharat Biotech International Limited
  • 11.10.1. Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Outlook
  • 11.10.4. Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13. Appendix

• 13.1. Related Research